WZWeina Zhang

Weina Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Weina Zhang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Ningling Wang

    Department of Hematology/Oncology Pediatrics the Second Affiliated Hospital of Anhui Medical University Hefei China

    4 shared publications
  • Jiashi Zhu

    Department of Hematology and Oncology Children's Hospital Affiliated to Shanghai Jiao Tong University Shanghai China

    3 shared publications
  • Xiaowen Zhai

    Children's Hospital of Fudan University, Shang Hai, China

    3 shared publications
  • Aiguo Liu

    Department of Pediatrics Huazhong University of Science and Technology Tongji Medical College Tongji Hospital Wuhan China

    2 shared publications
  • Changda Liang

    14Department of Hematology/Oncology, Jiangxi Provincial Children's Hospital, Nanchang, China

    2 shared publications
  • Cheng Cheng

    St. Jude Children's Research Hospital, Memphis, Tennessee, United States

    2 shared publications

Latest Publications

  • Open Access

    Temporal Improvement in Post‐Relapse Survival Among Children With Relapsed B‐Cell Acute Lymphoblastic Leukemia in China: A Multicenter Retrospective Cohort Study, 2015–2023

    by Jinhua Chu, Chengzhu Liu, Bohan Li, Wenyu Yang, Yanjing Tang, Weina Zhang, Aijun Zhang, Aiguo Liu, Yongjun Fang, Frankie W. T. Cheng, et al.

    Objective: Whether post‐relapse survival in pediatric B‐cell acute lymphoblastic leukemia (B‐ALL) has improved in contemporary Chinese practice remains unclear. We evaluated temporal changes in survival and salvage treatment patterns among children with relapsed B‐ALL treated during 2015–2023. Methods: This multicenter retrospective cohort study included children and adolescents with relapsed B‐ALL, grouped by year of first relapse into Stage I (2015–2017), Stage II (2018–2020), and Stage III (2021–2023). The primary endpoint was overall survival (OS) from first relapse. Sensitivity analysis used a composite endpoint of death or treatment abandonment. Kaplan–Meier analysis, multivariable Cox regression, and inverse probability of treatment weighting (IPTW) were applied. Results: Among 585 reviewed records, 527 patients had B‐ALL with available first‐relapse dates, and 504 comprised the primary survival cohort: 72 in Stage I, 309 in Stage II, and 123 in Stage III. Relapse characteristics and treatment patterns changed across eras, with increasing use of chimeric antigen receptor T‐cell therapy and targeted therapies in later periods. The 24‐month OS rates were 52.1% (95% CI, 41.3%–65.6%), 66.5% (95% CI, 61.1%–72.4%), and 82.9% (95% CI, 75.3%–91.2%) for Stages I, II, and III, respectively (log‐rank p < 0.001). In multivariable analysis, Stage III was associated with lower mortality than Stage I (HR, 0.421; 95% CI, 0.222–0.797; p = 0.008), whereas Stage II was not significantly associated with reduced mortality (HR, 0.825; 95% CI, 0.540–1.262; p = 0.375). Early or very early relapse, bone marrow relapse, combined relapse, and other or unknown relapse sites were associated with worse outcomes. Findings were consistent in sensitivity and IPTW‐weighted analyses. Conclusion: Post‐relapse survival in pediatric B‐ALL improved substantially across treatment eras, with the clearest benefit in Stage III. This improvement coincided with increasing use of chimeric antigen receptor T‐cell and targeted therapies. Early relapse and marrow‐involving relapse remained major adverse prognostic factors.

  • Open Access

    A low- versus standard-dose regimen as induction for pediatric AML: a multicenter, randomized noninferiority trial

    by Li Gao, Xiaowen Zhai, Ningling Wang, Ning Liao, Peifang Xiao, Fang Xu, Minghua Yang, Xueju Xu, Qi An, Jixia Luo, et al.

    Intensive chemotherapy is standard for AML but carries high risks of life-threatening complications, particularly in vulnerable patients. We aimed to compare the efficacy and safety of a low-dose chemotherapy (LDC) regimen for induction of AML. A randomized, multicenter, noninferiority trial was conducted in patients aged <18 years with AML. Patients received low-dose cytarabine, mitoxantrone or idarubicin, and G-CSF (LDC) or standard-dose induction chemotherapy (SDC) (cytarabine, daunomycin, and etoposide). All patients received post-remission consolidation with standard chemotherapy and/ or hematopoietic stem cell transplantation. The primary endpoint was to compare response rates between treatments. The secondary endpoints were to compare the outcomes, toxicity, and safety of the LDC and SDC regimens. The two treatment arms showed no significant differences in outcomes. Complete remission (CR/CRi) rates after induction were 95.1% and 95.3% in the LDC and SDC arms, respectively. Measurable residual disease < 0.1% after induction II was observed in 87.4% and 87.1% of patients in the LDC and SDC arms, respectively. Median time to neutrophil and platelet recovery was significantly shorter among patients receiving the LDC regimen. Patients in the LDC arm had a 4-year overall survival (OS) of 81.3% vs. 83.6% (P = .611) and a 4-year event-free survival (EFS) of 61.5% vs. 63.1% (P = .832). In conclusion, the LDC regimen was well tolerated and was associated with CR, EFS, and OS rates that were not inferior to those of patients treated with the SDC regimen. The trial was registered at Chinese Clinical Trial Registry (ChiCTR1800015883).


  • Multi-scale transcriptomics analysis reveals MHC suppression in MEF2D fusion positive B-cell acute lymphoblastic leukemia

    by Weina Zhang, Yongjing Liu, Xinhua Xiao, Qingqing Zheng, Yali Xie, Jinping Li, Tao Zeng, Yuliang Wang, Hua Jiang, Jinyan Huang


  • Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL

    by Changcheng Chen, Jiaoyang Cai, Xuedong Wu, Qun Hu, Xiaoyan Wu, Xia Guo, Shaoyan Hu, Xiaowen Zhai, Benquan Qi, Weina Zhang, et al.

    Asparaginase-associated pancreatitis (AAP) is a significant complication in pediatric acute lymphoblastic leukemia (ALL) therapy, often leading to treatment delays or discontinuation. This study aimed to identify AAP risk factors, assess outcomes after first and second episodes, and evaluate the impact of asparaginase rechallenge. We retrospectively analyzed 7640 patients (aged 1 month to 18 years) treated under the Chinese Children Cancer Group ALL 2015 protocol. Patients were stratified as low risk (LR), intermediate risk (IR), or high risk (HR) based on clinical features and measurable residual disease (MRD). AAP was categorized as early or late onset depending on treatment phase. Older age and IR/HR status were independent risk factors for AAP. The cumulative AAP incidence was 2.2% in LR and 5.8% in IR/HR groups. Among 298 patients who developed AAP, 92 were rechallenged with asparaginase; second episodes occurred in 20.8% of LR and 33.8% of IR/HR patients, with no increase in severity. Lack of rechallenge and day 46 MRD of ≥0.01% were independently associated with inferior event-free survival (EFS). Among patients with early-onset AAP, those who were rechallenged had superior 5-year EFS than those who were not rechallenged (80.1% vs 60.2%; P = .003). Similarly, among IR/HR group, those who were rechallenged had better 5-year EFS than those who were not rechallenged (82.4% vs 60.6%; P = .004). IR/HR patients with early-onset AAP who were not rechallenged had especially poor outcomes (5-year EFS, 53.3%). These findings support considering asparaginase rechallenge in IR/HR patients with early-onset AAP when alternative therapies are limited. This trial was registered at www.chictr.org.cn as #ChiCTR2000032211.


  • Open Access

    A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG‐ALL‐2015

    by Wenting Gan, Weina Zhang, Jiaoyang Cai, Xiaofan Zhu, Jie Yu, Peifang Xiao, Ju Gao, Yongjun Fang, Changda Liang, Xue Li, et al.

    Objective: Acute abdomen presents a significant challenge in the treatment of childhood acute lymphoblastic leukemia (ALL), potentially leading to treatment failure and treatment‐related mortality. Results from the multicenter study of CCCG‐ALL‐2015 showed significant improvements in overall survival (OS) and event‐free survival (EFS) for childhood ALL. However, the primary aim of this study was to determine the incidence, risk factors, and clinical impact of acute abdomen in the CCCG‐ALL‐2015 protocol, with the ultimate goal in the future of establishing evidence‐based preventive strategies to reduce its occurrence.Methods: Patients participating in the CCCG‐ALL‐2015 protocol from January 1, 2015, to December 31, 2019, were included in this analysis. The occurrence of acute abdomen in 7640 patients with ALL was analyzed retrospectively. The data was collected in August 2023 from the Data Center. Acute abdomen analyzed in this study included: acute pancreatitis, acute appendicitis, ileus, enterobrosis, enterorrhagia, peritonitis, enteritis, and others (urinary calculus, anaphylactoid purpura, cholecystitis). The clinical data of patients with acute abdomen were extracted from the database and analyzed.Results: A total of 7640 patients were recruited in the study, and 512 (6.7%) patients diagnosed with acute abdomen were identified. Of the 512 patients, 50 patients experienced two episodes of acute abdomen, 5 patients had three episodes, and 2 patients had four episodes. Among different types of acute abdomen, the incidence of acute pancreatitis was the highest (4.0%), followed by ileus (1.2%) and acute appendicitis (0.7%). There was no difference in the incidence of acute abdomen between males and females (6.6% vs. 6.9%, p = 0.64). The incidence of acute abdomen was associated with age, and patients older than 10 years had a significantly higher incidence rate than those less than 1 year and 1–10 years old (13.0% vs. 5.7%, p < 0.0001). The incidence rate of enterorrhagia was significantly higher in patients less than 1 year and older than 10 years than that in patients aged 1–10 years old (1.4% vs. 0.4%, p < 0.0001). The incidence of acute abdomen in the intermediate or high‐risk (I/HR) group was higher than that in the low‐risk (LR) group (9.9% vs. 3.7%, p < 0.001). Acute abdomen mainly occurred in the induction remission phase (57.3%) and the continuation and reinduction phase (39.3%). A total of 16 patients died from acute abdomen, including four patients in the LR group and 12 patients in the I/HR group. Among the different types of acute abdomen, the mortality rate of enterorrhagia was the highest (16.7%), followed by enterobrosis (9.1%).Conclusion: This multicenter study investigates the frequency, risk factors, and impact of acute abdomen in the CCCG‐ALL‐2015 protocol, the largest pediatric ALL study in China. We identified acute abdomen in 6.7% of patients, with the highest incidence during the induction remission phase and in older children and those with intermediate or high‐risk ALL. Acute pancreatitis was the most common type, while enterorrhagia had the highest mortality. These findings underscore the need for heightened vigilance and proactive management of acute abdomen to improve outcomes in children with ALL.Trial Registration: Chinese Clinical Trial Registry: ChiCTR‐IPR‐14005706


  • Open Access

    Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion

    by Ming Zhang, Hao Zhang, Zhihui Li, Ling Bai, Qianqian Wang, Jianfeng Li, Minghao Jiang, Qing Xue, Nuo Cheng, Weina Zhang, et al.

    Recurrent MEF2D fusions with poor prognosis have been identified in B-cell precursor ALL (BCP-ALL). The molecular mechanisms underlying the pathogenic function of MEF2D fusions are poorly understood. Here, we show that MEF2D-HNRNPUL1 (MH) knock-in mice developed a progressive disease from impaired B-cell development at the pre–pro-B stage to pre-leukemia over 10 to 12 months. When cooperating with NRASG12D, MH drove an outbreak of BCP-ALL, with a more aggressive phenotype than the NRASG12D-induced leukemia. RNA-sequencing identified key networks involved in disease mechanisms. In chromatin immunoprecipitation–sequencing experiments, MH acquired increased chromatin-binding ability, mostly through MEF2D-responsive element (MRE) motifs in target genes, compared with wild-type MEF2D. Using X-ray crystallography, the MEF2D-MRE complex was characterized in atomic resolution, whereas disrupting the MH-DNA interaction alleviated the aberrant target gene expression and the B-cell differentiation arrest. The C-terminal moiety (HNRNPUL1 part) of MH was proven to contribute to the fusion protein’s trans-regulatory activity, cofactor recruitment, and homodimerization. Furthermore, targeting MH-driven transactivation of the HDAC family by using the histone deacetylase inhibitor panobinostat in combination with chemotherapy improved the overall survival of MH/NRASG12D BCP-ALL mice. Altogether, these results not only highlight MH as an important driver in leukemogenesis but also provoke targeted intervention against BCP-ALL with MEF2D fusions.